Bivision, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel targeted radiopharmaceuticals to address significant unmet medical needs. Bivision has a diversified R&D pipeline cross different stage of drug discovery and development process. Its lead drug candidate JH02, a Lutetium-177 labeled small molecule ligand targeting Prostate Specific Membrane Antigen (PSMA) for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) has been approved by both FDA and CDE and currently is under Phase I/II clinical trial
